Your browser doesn't support javascript.
loading
Biweekly vinorelbine and tegafur/uracil in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: GEICAM 2000-02 phase II study
Antón, A; Barnadas, A; Florián, J; Ribelles, N; Lomas, M; Lao, J; González-Quintás, A; Margelí, M; Paules, AB; Gayo, J; Ramos, M.
Afiliação
  • Antón, A; Hospital Universitario Miguel Servet. Zaragoza. Spain
  • Barnadas, A; Hospital de la Santa Creu i Sant Pau. Barcelona. Spain
  • Florián, J; Hospital de Barbastro. Huesca. Spain
  • Ribelles, N; Hospital Universitario Virgen de la Victoria. Málaga. Spain
  • Lomas, M; Hospital General de Jaén. Jaén. Spain
  • Lao, J; Hospital Universitario Miguel Servet. Zaragoza. Spain
  • González-Quintás, A; Centro Oncológico de Galicia. A Coruña. Spain
  • Margelí, M; Hospital Germans Trias i Pujol. Badalona. Spain
  • Paules, AB; Pierre Fabre Ibérica SA. Barcelona. Spain
  • Gayo, J; Pierre Fabre Ibérica SA. Barcelona. Spain
  • Ramos, M; Centro Oncológico de Galicia. A Coruña. Spain
Clin. transl. oncol. (Print) ; 13(4): 281-286, abr. 2011. tab
Artigo em Inglês | IBECS | ID: ibc-124436
Biblioteca responsável: ES1.1
Localização: BNCS
ABSTRACT

INTRODUCTION:

To assess the efficacy and safety profile of biweekly vinorelbine and tegafur/uracil (UFT) as treatment in patients with metastatic breast cancer previously treated with anthracyclines and taxanes. PATIENTS AND

METHODS:

Patients with histologically confirmed breast cancer, measurable disease, no more than one prior chemotherapy regimen for metastatic disease, an Eastern Cooperative Oncology Group (ECOG) performance status ≤2, and adequate bone marrow, renal and liver function were eligible. Patients received vinorelbine (30 mg/m(2) on day 1) and UFT (250 mg/m(2) daily) every two weeks for 12 cycles unless progression or unacceptable toxicity was observed.

RESULTS:

Thirty-seven patients were included and received 311 cycles of chemotherapy. Efficacy and toxicity analyses were carried out on an intention-to-treat basis. The overall response rate was 35% (95% CI 20-53). With a median follow-up of 18.6 months (95% CI 1.0-74.3), the median time to progression was 7.0 months (96% CI 5.2-8.9) and the median overall survival was 19.4 months (95% CI 11.1-27.8). The most common severe toxicities were neutropenia (38% of patients) and asthenia (11% of patients).

CONCLUSION:

The combination of biweekly vinorelbine and UFT in patients with metastatic breast cancer pretreated with anthracyclines and taxanes is a well tolerated and effective regimen. AEMPS Trial Registration No. 00-0534 (AU)
Assuntos
Buscar no Google
Coleções: Bases de dados nacionais / Espanha Base de dados: IBECS Assunto principal: Uracila / Vimblastina / Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Estudos Multicêntricos como Assunto / Tegafur / Ensaios Clínicos Fase II como Assunto / Intervalo Livre de Doença Tipo de estudo: Ensaio clínico controlado / Estudo de avaliação Limite: Adulto / Idoso / Feminino / Humanos Idioma: Inglês Revista: Clin. transl. oncol. (Print) Ano de publicação: 2011 Tipo de documento: Artigo Instituição/País de afiliação: Centro Oncológico de Galicia/Spain / Hospital General de Jaén/Spain / Hospital Germans Trias i Pujol/Spain / Hospital Universitario Miguel Servet/Spain / Hospital Universitario Virgen de la Victoria/Spain / Hospital de Barbastro/Spain / Hospital de la Santa Creu i Sant Pau/Spain / Pierre Fabre Ibérica SA/Spain
Buscar no Google
Coleções: Bases de dados nacionais / Espanha Base de dados: IBECS Assunto principal: Uracila / Vimblastina / Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Estudos Multicêntricos como Assunto / Tegafur / Ensaios Clínicos Fase II como Assunto / Intervalo Livre de Doença Tipo de estudo: Ensaio clínico controlado / Estudo de avaliação Limite: Adulto / Idoso / Feminino / Humanos Idioma: Inglês Revista: Clin. transl. oncol. (Print) Ano de publicação: 2011 Tipo de documento: Artigo Instituição/País de afiliação: Centro Oncológico de Galicia/Spain / Hospital General de Jaén/Spain / Hospital Germans Trias i Pujol/Spain / Hospital Universitario Miguel Servet/Spain / Hospital Universitario Virgen de la Victoria/Spain / Hospital de Barbastro/Spain / Hospital de la Santa Creu i Sant Pau/Spain / Pierre Fabre Ibérica SA/Spain
...